Claris Lifesciences (CLL) along with its wholly owned subsidiary Claris Injectables Limited (CIL) has informed that it underwent a successful USFDA Pharmacovigilance (PV) audit from Monday 29th May to Wednesday 31st May with No Observation (i483s).
The above information is a part of company’s filings submitted to BSE.